Last reviewed · How we verify
Felodipine sustained-release tablet — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Felodipine sustained-release tablet (Felodipine sustained-release tablet) — Lee's Pharmaceutical Limited.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Felodipine sustained-release tablet TARGET | Felodipine sustained-release tablet | Lee's Pharmaceutical Limited | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Felodipine sustained-release tablet CI watch — RSS
- Felodipine sustained-release tablet CI watch — Atom
- Felodipine sustained-release tablet CI watch — JSON
- Felodipine sustained-release tablet alone — RSS
Cite this brief
Drug Landscape (2026). Felodipine sustained-release tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/felodipine-sustained-release-tablet. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing